Technology Appraisal Guidance No. 101
Source: National Institute for Health and Care Excellence
1.1 Docetaxel is recommended, within its licensed indications, as a treatment option for men with hormone-refractory metastatic prostate cancer only if their Karnofsky performance-status score is 60% or more.
1.2 It is recommended that treatment with docetaxel should be stopped:
- at the completion of planned treatment of up to 10 cycles, or
- if severe adverse events occur, or
- in the presence of progression of disease as evidenced by clinical or laboratory criteria, or by imaging studies.
1.3 Repeat cycles of treatment with docetaxel are not recommended if the disease recurs after completion of the planned course of chemotherapy.
The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at http://www.nice.org.uk/guidance/ta101
Copies of the document can also be obtained by contacting 0845 003 7783 or emailing email@example.com and quoting reference number N1056.
This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.
Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email: firstname.lastname@example.org
Docetaxel for the Treatment of Hormone-Refractory Metastatic Prostate Cancer.
Issue Date: June 2006
Review Date: June 2009